This site is intended for healthcare professionals
Biosimilars in retinal disease Learning Zone

Fast facts

Read time: 40 mins
Last updated:28th Jul 2022
Published:28th Jul 2022

Join Dr Ashish Sharma, an ophthalmologist at Lotus Eye Hospital and Institute in India, to learn some fast facts about biosimilars in retinal disease.

  • Expand your knowledge on the biosimilar development and approval process, and learn why biosimilars have only recently arrived on the market for retinal disease
  • Since the first ophthalmology biosimilar was approved in Europe and the US, learn about its clinical effectiveness and safety profile, and other biosimilars in the pipeline
  • Explore how early and sustained treatment can achieve better outcomes for patients with retinal disease, and how biosimilars can improve access to care

The basics of biosimilars

Can biosimilars be relied upon to achieve similar treatment outcomes to reference biologics?

 
1

Biosimilar development and approval

How does the biosimilar development compare to that of reference biologics?

 
3

Which biosimilars are approved for retinal disease in Europe and the US?

Which anti-VEGF biosimilars are approved in Europe and the US, and what others are in development?

 

Why have biosimilars only recently arrived on the market for retinal disease?

 
3

What’s the evidence for biosimilars in retinal disease?

How does efficacy of anti-VEGF biosimilars compare to that of their reference biologics in retinal disease?

 

How does the safety profile of anti-VEGF biosimilars compare to their reference biologics?

 
3

How can biosimilars benefit patients with retinal disease?

What are the benefits of ophthalmology biosimilars for clinicians and patients?

 

Is there evidence for a correlation between delayed treatment and visual acuity in retinal disease?

 

Can biosimilars improve access to care for patients with retinal disease?

 
3

Integrating biosimilars into practice

What are some key points to discuss with patients when considering a biosimilar for retinal disease?

 

What are some key considerations when switching from a reference medicine to a biosimilar for retinal disease?

 
3

Meet the expert

Dr Ashish Sharma

Dr Sharma is an ophthalmologist at Lotus Eye Hospital in Coimbatore, India. He has published over 90 peer-reviewed articles and book chapters, and is principal investigator on an EMA and FDA phase 3 clinical trial of newer anti-VEGFs. He is also on the reviewing and editorial board of high impact ophthalmology journals. He has been awarded an International Ophthalmologist Education Award by American Academy of Ophthalmology Board of trustees and Ophthalmic Hero of India by All India Ophthalmic Society.

Disclosures: Dr Sharma has been a consultant and speaker for Intas, Lupin, Novartis and Bayer

Welcome: